/GERN
GERN Stock - Geron Corporation
Healthcare|BiotechnologyNASDAQ
$1.33-0.75%
$0.01 (-0.75%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+200.8%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GERN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.32 – $1.34
TARGET (TP)$4.00
STOP LOSS$1.22
RISK/REWARD1:24.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$3.68
52W Low$1.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $76.99M | $237,000 | $596,000 | $1.39M | $253,000 |
| Gross Profit | $75.74M | $237,000 | $596,000 | $1.39M | $-49,799,000 |
| Gross Margin | 98.4% | 100.0% | 100.0% | 100.0% | -19683.4% |
| Operating Income | $-173,732,000 | $-193,944,000 | $-138,550,000 | $-113,999,000 | $-76,913,000 |
| Net Income | $-174,572,000 | $-184,127,000 | $-141,901,000 | $-116,112,000 | $-75,617,000 |
| Net Margin | -226.7% | -77690.7% | -23808.9% | -8335.4% | -29888.1% |
| EPS | $-0.27 | $-0.32 | $-0.37 | $-0.37 | $-0.28 |
Company Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
62%
Hold / Neutral
4
31%
Sell / Underperform
1
8%
Analyst Consensus🟡 Mixed
8 Bullish5 Neutral/Bearish
Price Targets
$5
Average Target
↑ 244.6% Upside
Now
$1
Low
$5
Average
$10
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | Goldman | Resumed | Sell | $1 |
| May 8th 2025 | Scotiabank | Downgrade | Sector Perform | $1.5 |
| February 27th 2025 | B. Riley Securities | Downgrade | Neutral | $2← $3.5 |
| February 26th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| November 5th 2024 | H.C. Wainwright | Initiation | Buy | $8 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| September 9th 2024 | Leerink Partners | Initiation | Outperform | $7 |
| April 30th 2024 | Robert W. Baird | Downgrade | Neutral | $4.5 |
| April 29th 2024 | TD Cowen | Initiation | Buy | $10 |
| March 15th 2024 | Needham | Reiterated | Buy | $5← $4 |
| September 12th 2023 | Goldman | Upgrade | Buy | $4 |
| March 28th 2023 | Goldman | Initiation | Neutral | $3 |
| October 28th 2022 | Wedbush | Initiation | Outperform | $5 |
| July 28th 2022 | B. Riley Securities | Resumed | Buy | $4 |
Earnings History & Surprises
GERNBeat Rate
72%
Last 18 quarters
Avg Surprise
+12.0%
EPS vs Estimate
Beats / Misses
13/3
2 met exactly
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q1 24
+10.0%
$-0.09vs$-0.10
Q2 24
+10.0%
$-0.09vs$-0.10
Q3 24
+9.1%
$-0.10vs$-0.11
Q4 24
+55.6%
$-0.04vs$-0.09
Q1 25
0.0%
$-0.04vs$-0.04
Q2 25
+25.0%
$-0.03vs$-0.04
Q3 25
+33.3%
$-0.02vs$-0.03
Q4 25
+18.2%
$-0.03vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.04 | $-0.03 | +18.2% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.03 | $-0.02 | +33.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.04 | $-0.03 | +25.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.04 | $-0.04 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $-0.09 | $-0.04 | +55.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.09 | $-0.09 | 0.0% | = MET |
Latest News
Geron Implements Strategic Restructuring, Cutting Workforce By One-Third And Incurring ~$18M In Charges
📉 NegativeBenzinga•Dec 16, 2025, 09:11 PM
Geron Corporation Announces Restructuring Plan Including Workforce Reduction Of Approximately One Third, Supports RYTELO US Commercial Strategy and Investment in Clinical Development
📉 NegativeBenzinga•Dec 11, 2025, 01:06 PM
Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis
📈 PositiveBenzinga•Dec 8, 2025, 01:09 PM
Needham Maintains Buy on Geron, Lowers Price Target to $4
➖ NeutralBenzinga•Nov 5, 2025, 05:23 PM
Geron Expects 2025 Operating Expenses Will Be Between $250M And $260M vs. Approximately $270M-$285M Prior
📈 PositiveBenzinga•Nov 5, 2025, 12:12 PM
Geron Q3 EPS $(0.03), Inline, Sales $47.227M Miss $52.881M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 12:10 PM
Geron GAAP EPS of -$0.03 in-line, revenue of $47.2M misses by $6.14M
📉 NegativeSeeking Alpha•Nov 5, 2025, 12:02 PM
Geron To Present New RYTELO Data On LR-MDS And Myelofibrosis At ASH 2025
📈 PositiveBenzinga•Nov 3, 2025, 02:11 PM
Geron's COO Andrew Grethlein To Depart On October 15, 2025
📉 NegativeBenzinga•Oct 13, 2025, 08:42 PM
Frequently Asked Questions about GERN
What is GERN's current stock price?
Geron Corporation (GERN) is currently trading at $1.33 per share. The stock has moved -0.75% today.
What is the analyst price target for GERN?
The average analyst price target for GERN is $4.00, based on 1 analyst.
What sector is Geron Corporation in?
Geron Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GERN's market cap?
Geron Corporation has a market capitalization of $0.85 billion, making it a small-cap company.
Does GERN pay dividends?
No, Geron Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to GERN for comparison